en · de · es · fr · pt
sr9009-notes.peptides9000.com › Faq › Background And Mechanism — Practical Notes

Background And Mechanism — Practical Notes

By Editorial Desk · published 2025-10-18 · last reviewed 2025-11-14 · Faq

WADA raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-11-14 and is reviewed periodically as new material appears.

Background and Mechanism

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

SR9009 Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SDerived from published structure.
Molecular weight437.94 g/molCalculated value.
AppearanceWhite to off-white solidTypical for purified research samples.
SolubilityDMSO, ethanol; low in waterClass: poorly water-soluble.
Typical storage-20 °C, desiccated, protected from lightLimits degradation.

Handling Storage and Quality Control

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Related pages on this site

Analytical Detection and Regulatory Status

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Detection, Regulation, and Misconceptions

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Analytical Detection and Storage

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Supporting material

Radium was discovered by Marie Skłodowska-Curie and her husband Pierre Curie on 21 December 1898 in a uraninite (pitchblende) sample from Jáchymov. While studying the mineral earlier, the Curies removed uranium from it and found that the remaining material was still radioactive. In July 1898, while studying pitchblende, they isolated an element similar to bismuth which turned out to be polonium. They then isolated a radioactive mixture consisting of two components: compounds of barium, which gave a brilliant green flame color, and unknown radioactive compounds which gave carmine spectral lines that had never been documented before. The Curies found the radioactive compounds to be very similar to the barium compounds, except they were less soluble. This discovery made it possible for the Curies to isolate the radioactive compounds and discover a new element in them. The Curies announced their discovery to the French Academy of Sciences on 26 December 1898. The naming of radium dates to about 1899, from the French word radium, formed in Modern Latin from radius (ray): this was in recognition of radium's emission of energy in the form of rays. The gaseous emissions of radium, radon, were recognized and studied extensively by Friedrich Ernst Dorn in the early 1900s, though at the time they were characterized as "radium emanations". In September 1910, Marie Curie and André-Louis Debierne announced that they had isolated radium as a pure metal through the electrolysis of pure radium chloride (RaCl2) solution using a mercury cathode, producing radium–mercury amalgam.

Intracrines play a crucial role in maintaining stem cell populations and guiding their differentiation into specialized cell types. Many stem cell regulatory proteins, including vascular endothelial growth factor (VEGF), high-mobility group protein B1 (HMGB1), and homeodomain transcription factors such as Pax6 and Oct3/4, operate through intracrine mechanisms. These factors establish intracellular feedback loops that sustain differentiation programs, ensuring that once a stem cell commits to a particular lineage, the developmental process continues even after the external signal is removed. For instance, VEGF, a well-known angiogenic factor, is also an intracrine that promotes the survival and differentiation of hematopoietic stem cells. In VEGF-deficient cells, survival and colony formation are impaired, but these defects can be rescued by restoring intracellular VEGF levels, highlighting the necessity of intracrine VEGF in stem cell regulation. Similarly, the homeodomain transcription factor Pdx-1 can be internalized by target cells, where it upregulates its own synthesis and drives pancreatic duct cells toward an insulin-producing phenotype, demonstrating the ability of intracrines to induce cell fate changes.

Amelio introduced benchmarking to evaluate productivity, restructured marketing strategies and reorganised management by introducing modern management practices and workplace environments. Amelio divided products into two divisions: Standard Products Group which comprised low-margin, logic and memory chips—commodity products which were more susceptible to cyclical demands and through which National Semiconductor had matured; and Communications & Computing Group which comprised high-margin, value-added analog and mixed-signal chips. Amelio's division of products seemed to prepare National Semiconductor for the eventual disposal of low-margin commodity products, which came to fruition later with the sale of a reconstituted Fairchild. National Semiconductor under Amelio chose to build a brand new eight-inch (200 mm) wafer fabrication plant in South Portland, Maine. It chose to divest itself of its then somewhat new plant in Migdal HaEmek, Israel, which became Tower Semiconductor. In 1995, Amelio was elected as the chairman of the board of directors of National Semiconductor. In 1996, Amelio accepted an invitation from Apple Computer, a customer of National Semiconductor, to join its board of directors. Troubles at Apple later prompted the board to invite Amelio to take on the position of CEO, which he accepted in February 1996. National Semiconductor announced the resignation of Amelio as the company's president, chairman and chief executive officer on February 2, 1996.

Sources: en.wikipedia.org

Supporting material

== M == macroevolution - macromolecular system - macromolecule - macrophage colony-stimulating factor - major histocompatibility complex - Malpighi body - Malpighi layer - marine biology - maslinic acid - mass spectrometer - maturation-promoting factor - mechanoreceptor - medicine - meiosis - melting point - membrane glycoprotein - membrane protein - membrane topology - membrane transport - memory B cell - memory T cell - Mendelian inheritance - metabolic pathway - metabolism - metabotropic glutamate receptor - metalloprotein - metaphase - metazoa - methionine - micelle - Michaelis-Menten kinetics - microbe - microbiology - microevolution - microfilament - microfilament protein - microsatellite - microscope - microtiter plate - microtubule-associated protein - mineralocorticoid receptor - minisatellite - mitochondrial membrane - mitochondrion - mitogen receptor - mitosis - mitotic spindle - mixture - modern evolutionary synthesis - molar volume - mole (unit) - molecular biology - molecular chaperone - molecular dynamics - molecular engineering - molecular evolution - molecular mechanics - molecular modelling - molecular orbital - molecular phylogeny - molecular sequence data - molecule - monoamine - monoclonal antibody - monomer - monosaccharide - monosaccharide transport protein - morphogenesis - morphogenetic field - mos gene - Mössbauer spectroscopy - MRI - MSH - mu opioid receptor - mu-chain immunoglobulin - mucin - Muller's ratchet - multiresistance - muscarinic receptor - muscle - muscle protein - mutagen - mutation - myc gene - mycology - myelin basic protein - myeloma protein - myosin

=== Stereochemistry === Oxprenolol is a chiral compound, the beta blocker is used as a racemate, e. g. a 1:1 mixture of (R)-(+)-oxprenolol and (S)-(–)-oxprenolol. Analytical methods (HPLC) for the separation and quantification of (R)-(+)-oxprenolol and (S)-(–)-oxprenolol in urine and in pharmaceutical formulations have been described in the literature.

== External links == "Chickenpox Vaccine Information Statement". U.S. Centers for Disease Control and Prevention (CDC). 10 August 2021. "Chickenpox (Varicella) Vaccination". U.S. Centers for Disease Control and Prevention (CDC). 25 February 2021. Chickenpox Vaccine at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

Rather than having players go through convoluted interface menus to modify their weapons, upgrade their plasmids, or buy items, these functions were split into vending machines scattered around the game world. Early in level development, the levels were roughly blocked out, but no one was happy with the art department's attempts to decorate them. A critical junction was a short experiment performed by level designer Jean Paul LeBreton and artist Hoagy de la Plante, setting themselves aside to co-develop a level that became part of the "Tea Garden" area in the released game, which Levine used as a prime example of a "great BioShock space", emphasizing the need for departments to work together. BioShock uses a heavily modified Unreal Engine 2.5 with some of the advanced technologies from Unreal Engine 3. Irrational had previous experience with modifying and expanding on the Unreal Engine in SWAT 4, and continued this advancement of the engine within BioShock. Given the game's setting, one significant improvement was made in the water systems, hiring a programmer and artist to focus on the water effects. Finley recalled that the team's deep familiarity with Unreal Engine was a blessing and curse, as it made prototyping the game very quick, but they were also more willing to accept fast-to-implement but inefficient solutions that ultimately cost more development time. BioShock also uses the Havok Physics engine that allows for the integration of ragdoll physics, and allows for more lifelike movement by elements of the environment.

Sources: en.wikipedia.org

Supporting material

=== Medicine === Californium-252 has also been used in the treatment of serious forms of cancer. For certain types of brain and cervical cancer, 252Cf can be used as a more cost-effective substitute for radium in brachytherapy.

Another independent approach is to use oligoadenylated anti-telomerase antisense oligonucleotides and ribozymes to target telomerase RNA, leading to the dissociation of the RNA and to apoptosis (Figure 5). The fast induction of apoptosis through antisense binding may be a good alternative to the slower telomere shortening.

=== Extant reptiles === The thorny devil (Moloch horridus) is similar in diet and activity patterns to the Texas horned lizard (Phrynosoma cornutum), although the two are not particularly closely related. Amphisbaenian skulls closely resemble those of caecilians and mammals. Modern crocodilians resemble prehistoric phytosaurs, champsosaurs, certain labyrinthodont amphibians, and perhaps even the early whale Ambulocetus. The resemblance between the crocodilians and phytosaurs in particular is quite striking; even to the point of having evolved the graduation between narrow- and broad-snouted forms, due to differences in diet between particular species in both groups. Death adders strongly resemble true vipers, but are elapids. Legless lizards evolved multiple times independently, including snakes, which are also legless lepidosaurs nested among legged lizards. Major examples of unrelated legless lizards include glass lizards (family Anguidae, related to legged alligator lizards) and flap-footed lizards (family Pygopodidae, related to geckos), which each may be mistaken for snakes. Large tegu lizards of South America have converged in form and ecology with monitor lizards, which are not present in the Americas. Anole lizards, with populations on isolated islands, are one of the best examples of both adaptive radiation and convergent evolution. Anoles on a given island evolve into multiple body types and ecological preferences, and the same set of body types appears in unrelated species across distant islands.

Evans' successor Lawrence Quincy Mumford took over in 1953. During his tenure, lasting until 1974, Mumford directed the initiation of construction of the James Madison Memorial Building, the third Library of Congress building on Capitol Hill. Mumford led the library during the government's increased educational spending. The library was able to establish new acquisition centers abroad, including in Cairo and New Delhi. In 1967, the library began experimenting with book preservation techniques through a Preservation Office. This has developed as the most extensive library research and conservation effort in the United States. During Mumford's administration, the last significant public debate occurred about the Library of Congress's role as both a legislative and national library. Asked by Joint Library Committee chairman Senator Claiborne Pell (D-RI) to assess operations and make recommendations, Douglas Bryant of Harvard University Library proposed several institutional reforms. These included expanding national activities and services and various organizational changes, all of which would emphasize the library's federal role rather than its legislative role. Bryant suggested changing the name of the Library of Congress, a recommendation rebuked by Mumford as "unspeakable violence to tradition." The debate continued within the library community for some time.

=== Thioredoxin reductase === Thioredoxin reductase uses a cysteine-selenocysteine pair to reduce the disulfide in thioredoxin. The selenocysteine is arranged in an unusual Sec-His-Glu catalytic triad, which tunes its pKa.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Is SR9009 a SARM?

No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.

Are there human trials of SR9009?

Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.

What is SR9009?

SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.

Network